872993-05-0
中文名稱
(4Z,7S,8S,9E,11E,13Z,15E,17S,19Z)-7,8,17-TRIHYDROXYDOCOSA-4,9,11,13,15,19-HEXAENOIC ACID
英文名稱
(4Z,7S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic acid
CAS
872993-05-0
分子式
C22H32O5
分子量
376.49
MOL 文件
872993-05-0.mol
872993-05-0 結(jié)構(gòu)式
基本信息
中文別名
消退素D1(4Z,7S,8R,9E,11E,13Z,15E,17S,19Z)-7,8,17-三羥基-4,9,11,13,15,19-二十二碳六烯酸
英文別名
RVD1Resolvin D1
resolvin D1, CID73755062
Resolvin D1 Exclusive
OIWTWACQMDFHJG-CCFUIAGSSA-N
Resolvin D1 MaxSpec? Standard
(4Z,7S,9E,11E,13Z,15E,17S,19Z)-7,8,17-trihydroxydocosa-4,9,11,13,15,19-hexaenoic acid
(4Z,7S,8S,9E,11E,13Z,15E,17S,19Z)-7,8,17-TRIHYDROXYDOCOSA-4,9,11,13,15,19-HEXAENOIC ACID
4,9,11,13,15,19-Docosahexaenoic acid, 7,8,17-trihydroxy-, (4Z,7S,8R,9E,11E,13Z,15E,17S,19Z)-
物理化學(xué)性質(zhì)
儲(chǔ)存條件Store at -80°C,protect from light
溶解度DMF: 50 mg/ml; Ethanol: 50 mg/ml; PBS (pH 7.2): 0.05 mg/ml
形態(tài)Liquid
顏色Colorless to light yellow
(4Z,7S,8S,9E,11E,13Z,15E,17S,19Z)-7,8,17-TRIHYDROXYDOCOSA-4,9,11,13,15,19-HEXAENOIC ACID價(jià)格(試劑級(jí))
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2024/11/08 | HY-125527 | (4Z,7S,8S,9E,11E,13Z,15E,17S,19Z)-7,8,17-TRIHYDROXYDOCOSA-4,9,11,13,15,19-HEXAENOIC ACID Resolvin D1 | 872993-05-0 | 25μg(265.6μM * 250μL in Ethanol) | 8500元 |
常見問題列表
生物活性
Resolvin D1 (RvD1) 是炎癥的一種內(nèi)源性促分解介質(zhì)，衍生自在急性炎癥的緩解階段的 omega-3二十二碳六烯酸。Resolvin D1 通過(guò)調(diào)節(jié)肌動(dòng)蛋白聚合來(lái)阻止促炎性中性粒細(xì)胞遷移，減少巨噬細(xì)胞中 TNF-α 介導(dǎo)的炎癥，并增強(qiáng)巨噬細(xì)胞對(duì)凋亡細(xì)胞的吞噬作用。靶點(diǎn)
|
Human Endogenous Metabolite
|
體外研究
Resolvin D1 (RvD1) (1-100 nM; 15 minutes) induces dose-dependent short-term functional changes in primary human macrophages. RvD1 triggers intracellular Ca 2+ release, blocks chemotactic migration, and stimulates phagocytosis of microbial particles with maximal efficiency at 10 nM. Resolvin D1 (0-500?nM; 72 hours) shows a strong inhibition of LPS-induced TRAP and cathepsin K expression by RvD1 at different concentrations in RAW264.7 macrophages.
體內(nèi)研究
Resolvin D1 (RvD1) (100-1000 ng; i.p.; daily on days 10) improves RA (rheumatoid arthritis) clinical endpoints in arthritic mice.
| Animal Model: | 18-20?g thirty 8-week-old female DBA/1J mice (collagen antibody-induced arthritis (CAIA)) |
| Dosage: | 100, 500, and 1000?ng (or 1000 ng, daily on days 4-10) |
| Administration: | i.p. injection; daily on days 10 |
| Result: | Exhibit a reduced arthritic score. |